James J. Bieker

The paper shows that STING and VDAC inhibitors reduce inflammation and ineffective erythropoiesis in a Nan mouse model by targeting metabolic dysregulation and cGAS-STING pathway activation.

The paper demonstrates that quantitative control of KLF1 expression can be achieved through genomic manipulation in human hematopoietic cells.

The paper identifies Ddx5/p68 as an activator of KLF1 through its interaction with the EHS1 enhancer element, suggesting its role in the enhanseosome complex for KLF1 expression.

The paper identifies a unique macrophage subset in mouse erythropoiesis defined by EKLF/KLF1 expression and describes its transient role in erythroblastic islands.

This study identifies how a KLF1 mutation alters DNA-binding specificity, leading to congenital dyserythropoietic anemia type IV by changing target gene activation patterns.